TITLE:
National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients

CONDITION:
Dwarfism, Pituitary

INTERVENTION:
NONE

SUMMARY:

      This study is a multicenter, open-label, observational, postmarketing surveillance study
      that will collect information on the use of Genentech GH preparations to treat GH-deficient
      subjects with optimal GH dosing during puberty.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 12 Years to 17 Years
Criteria:

        Inclusion Criteria:

          -  Adolescent boys who are GH deficient and Tanner Stage 2 or greater (testes 3 mL or
             greater)

          -  Adolescent girls who are GH deficient and breast Tanner Stage 2 or greater

          -  Current treatment with GH dose of 0.4 to 0.7 mg/kg/wk

          -  Ability to keep follow-up appointments throughout the study

          -  Willingness to remain on therapy until epiphyseal closure is achieved

          -  Prior enrollment in NCGS Core Study 85-036

        Exclusion Criteria:

          -  Treatment with non-Genentech GH preparation

          -  Closed epiphyses

          -  Active neoplasia

          -  Treatment with insulin for diabetes
      
